Barr Launches DDAVP Generic With 180-Day Exclusivity
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves Barr’s ANDA for Sanofi-Aventis’ bed-wetting therapy DDAVP. Approval comes five months after Barr prevailed in a patent dispute with DDAVP manufacturer Ferring.
You may also be interested in...
FDA Chief Counsel Bradshaw's "Practical" Approach Applauded By Barr
Barr CEO Bruce Downey is praising FDA Chief Counsel Sheldon Bradshaw's attitude towards issues affecting the generic drug industry
FDA Chief Counsel Bradshaw's "Practical" Approach Applauded By Barr
Barr CEO Bruce Downey is praising FDA Chief Counsel Sheldon Bradshaw's attitude towards issues affecting the generic drug industry
Barr Says Citizen Petition Is Remaining Obstacle To DDAVP Generic Approval
Federal court ruling that Sanofi-Aventis patents on desmopressin tablets are invalid and not infringed "effectively ends" 30-month stay of approval on Barr's ANDA for the bed-wetting therapy, generic firm says. A pending citizen petition seeks to establish specific bioequivalence requirements for DDAVP generics.